


Supplementary Figure 1A. Recombinant RHA is homogenously purified. The purified RHA was loaded to Gel Filtration column containing HiLoad 26/600 Superdex200pg (320 ml) matrix. The sharpness and symetric distribution of the both sides of 280 nm peak demonstrated that purified RHA fractions were homogenously.



Supplementary Figure 1B: Negative controls for RHA dependent helicase activity. i. Without RHA or with Heat Inactivated (H.I) RHA or without ATP or without MgCl₂ strand seperation of dsRNA cannot happen. ii. Non-helicase protein, Ezrin, cannot drive helicase reaction.



ds

SS



ds SS


iii

i


Time (min)

СТР


0 1



Supplementary Figure 1C. RHA utilizes i.CTP, ii.UTP and iii. GTP in addition to ATP to drive helicase reaction.



Supplementary Figure S2: A. Coomassie blue stained gel showed the recombinant EWS-FLI1 after purification. B. In two minute reaction, recombinant EWS-FLI1 facilitates the annealing activity of RHA in a dose dependent manner. 10 nM EWS-FLI1 increased the annealing activity of RHA by four fold in 2 minutes. 10 nM EWS-FLI1, alone, facilitated the annealing of ssRNA significantly in 2 minutes. C. EWS-FLI1 did not inhibit the ATPase activity of RHA. A fluorescent substrate was used to measure the ATPase activity of 2 nM RHA and 2 nM RNA (black line) and 2 nM RHA with 2 nM EWS-FLI1 and 2 nM RNA (red line). The reactions without RNA, such as RHA (cayenne line), EWS-FLI1 and RHA (maroon line), EWS-FLI1 alone (green line) and EWS-FLI1 buffer with RHA (gray line) did not have ATPase activity.



Supplementary Figure 3: Increased salt decreased RNA binding affinity of EWS-FLI1. The RNA binding of EWS-FLI1 was measured in the 140 and 210 nM NaCl containing binding reactions. EWS-FLI1 protein concentration ranged from 0.1 to 312 nM by 5 fold. Free and protein bound RNA was resolved by 6% native PAGE.


С	atRAPID	http://service.tarta	aglialab.com/			Supplementary Figure	e 4A
1	MASTD	YSTYSQAAAQQG	YSAYTAQPTQG	GYAQTTQAYGQ	QSYGTYGQ	PTDVSYTQAQTTTY	60
61	GQTAY	ATSYGQPPTGYTI	PTAPQAYSQP\	/QGYGTGAYD		ASYAAQSAYGTQ	120
121	PAYPAY	'GQQPAATAPTRP	QDGNKPTETSC	QPQSSTGGYN	QPSLGYGQS	NYSYPQVPGSYPM	180
181	QPVTA	PSYPPTSYSSTC	PTSYDQSSYS(QQNTYGQPSS	YGQQSSYG	QQSSYGQQPPTSYP	240
241	PTGSY	SQAPSQYSQQSS	SYGQQPSYDS	VRRGAWGNNI	MNSGLNKSP	PLGGAQTISKNTEQF 4	300
301	PQPDP 4	YQILGPTSSRLAN	PGSGQIQLWQF	FLLELLSDSAN	ASCITW <mark>EGTI</mark>	IGEFKMTDPDEVARI 1	<u>२</u> 363
364	WGERK 2	(SKPNMNYDKLSF	RALRYYYDKNIM	TKVHG (RYAY		ALQPHPTESSMYKY	 424
425	PSDISY	MPSYHAHQQKVI	NFVPPHPSSMP			GIYPNPNVPRHPNT	485
486	HVPSH						495
	einstein.c	s.iastate.edu/RNA	BindR SVM I	based prediction	on	Supplementary Figur	e 4B
		TYSQAAAQQGY 0000000000000000			40101104	PTDVSYTQAQTTTY	
						QASYAAQSAYGTQ 0000000000000000	
						NYSYPQVPGSYPM 0000000000000000	
-		-				QSSYGQQPPTSYP 0000000000000000	
						GGAQTISKNTEQR	
P 0	QPDPYC 0 0 0 0 0 0 0	00000000000000000000000000000000000000	GSGQIQLWQF 0000000000000	LLELLSDSAN 0 0 0 0 0 0 0 0 0 0 0	IASCITWEG	INGEFKMTDPDEV 000000000000000000000000000000000000	
A 0	RR WGE I 0 0 1 1 1	RKSKPNMNYDK 1111 1111 110	LSRALRYYYD 1111101000	KNI MTKVHG	(R YA Y KFDF 10010000	HGIAQ ALQ PHPTES 0 0 0 0 0 1 0 1 0 0 0 0 0	S 0 0
						ISPTGGIYPNPNVP	
		/P SH LG SY Y 0 1100 110					

www.//bioinfo.ggc.org/cgi-bin/bindn/bindn.pl

Sequence: Prediction: Confidence:	MASTDYSTYSQAAAQQGYSAYTAQPTQGYAQTTQAYGQQSYGTYGQPTDVSYTQAQTTTY +++++-+++-++-++++++++++++++++
Sequence: Prediction: Confidence:	GQTAYATSYGQPPTGYTTPTAPQAYSQPVQGYGTGAYDTTTATVTTTQASYAAQSAYGTQ +++-+-+++++++++++++++++++++++++++++++
Sequence: Prediction: Confidence:	PAYPAYGQQPAATAPTRPQDGNKPTETSQPQSSTGGYNQPSLGYGQSNYSYPQVPGSYPM ++-++++++++++++++++++++++++++++++
Sequence: Prediction: Confidence:	QPVTAPPSYPPTSYSSTQPTSYDQSSYSQQNTYGQPSSYGQQSSYGQQSSYGQQPPTSYP ++-++++++++++++++++++++++++++++++++
Sequence: Prediction: Confidence:	PTGSYSQAPSQYSQQSSSYGQQPSYDSVRRGAWGNNMNSGLNKSPPLGGAQTISKNTEQR ++++++++++++++++++++++++++++++++++++
Sequence: Prediction: Confidence:	PQPDPYQILGPTSSRLANPGSGQIQLWQFLLELLSDSANASCITWEGTNGEFKMTDPDEV ++++++-++-+
Sequence: Prediction: Confidence:	ARRWGERKSKPNMNYDKLSRALRYYYDKNIMTKVHG -++++++++++++++++++++++++++++++++++++
Sequence: Prediction: Confidence:	MYKYPSDISYMPSYHAHQQKVNFVPPHPSSMPVTSSSFFGAASQYWTSPTGGIYPNPNVP -+++++++++-+++++++
Sequence: Prediction: Confidence:	RHPNTHVPSHLGSYY +-++++++ 824565625444523

Supplementary Figure 4: The RNA binding site prediction results for EWS-FLI1.

A. The prediction result of catRAPID (http://service.tartaglialab.com/), B. The prediction result of RNABindR (einstein.cs.iastate.edu/RNABindR) C. The prediction result of BindN (//bioinfo.ggc.org/cgi-bin/bindn/bindn.pl). The boxed regions in all three prediction results show the ets-binding domain of FLI1 protein.




wt Ets-DNA sequence

5'-ATG TAG ACC **<u>GGA A</u>**GT AAC TA-3' 3'-TAC ATC TGG <u>CCT T</u>CA TTG AT-5'

mut Ets-DNA sequence

5'-ATG TAG ACC **GCT A**GT AAC TA-3' 3'-TAC ATC TGG **CGA T**CA TTG AT-5'


Supplementary Figure 5: The RNA binding of EWS-FLI1 could be partially through the *ets*-DNA binding domain. Wild- type DNA containing GGAA (bold and underlined) or mutant GCTA sequences (bold and boxed) was included in the RNA binding assays of EWS-FLI1. 30 nM EWS-FLI1 was complexed with varying concentration from 0 to 3250 nM of the ets-DNA before the addition of dsRNA. The protein-RNA complexes were resolved with 6% native PAGE.



Supplementary Figure 6: YK-4-279 does not inhibit the helicase activity of RHA. 30 $\,\mu\text{M}$ YK-4-279 was added to helicase assay containing 1 nM RHA.


RHA		EWS-FLI1	A by	1345 by both RHA and EWS-FLI1		Supplem	entary Figure 7	
	GO Term Enrichment				_	P-value		
	1.	345	Cell-cell adhesion Inflammatory response				8.0x10⁻ ⁶ 1.8x10⁻⁵	
Cor	ripts pull-down by Negative regulation of vasculature Regulation of vasoconstriction				3.3x10⁻⁵			
	both EWS-	ELI1 and RHA Detection of stimulus involved in s Neuronal action potential			olved in ser	sensory perception 7.4x10 ⁻⁵ 1.1x10 ⁻⁴		
	+ YK-4-279	4-279 Humoral immune response Positive regulation of blood circ			2.0x10 ⁻⁴ 2.0x10 ⁻⁴			
	EWS-FLI1	Cell-cell signaling			4.4x10 ⁻⁴ 7.8x10 ⁻⁴			
				Negative regulation of notch sig Regulation of ion transport		IY	8.0x10 ⁻⁴	
В		с		D		E		
615 by both RHA and EWS-F	LI1	306 by EWS-FLI1		243 by RHA			B1 RNA HA nor EWS-FLI1	
GO Term Enrichment	P-value	GO Term Enrichment	P-value	GO Term Enrichment	P-value	GO Term Enrichme Regulation of JAK-STAT cascade		
Detection of chemical stimulus involved in sensory perception of smell	9.8x10 ⁻⁷	Cell communication	5.7x10 ⁻⁴	Histone H4K20 demethylation	6.0x10 ⁻⁴		T 8.4x10 ⁻⁴	
Leukotrine metabolic process	1.0x10⁻⁵	Single organism signaling	4.7x10 ⁻⁴	Negative regulation of megakaryocyte	3.3x10⁴	Cascaut	5	
Phosphatidylglycerol metabolic process	1.0x10⁻⁵			differentation				
Phosphatidic acid biosynthetic process	7.2x10 ⁻⁴							
Positive regulation of antigen processing and presentation	6.0x10 ⁻⁴							
Endochondral ossification	3.3x10 ⁻⁴							
Icosanoid biosynthetic process	3.2x10 ⁻⁴							
Potassium ion transmembrane transport	1.8x10 ⁻⁴							

Supplementary Figure 7: RIP-seq determined overlapping transcripts from either EWS-FLI1 or RHA complexes. A. Gene Ontology term enrichment analysis of RNA found in both RHA and EWS-FLI1 protein complexes. B. The analysis of RNA continued to be overlapping from both RIP after YK-4-279 treatment. C. The GO analysis of RNA only present with EWS-FLI1 RIP after YK-4-279 treatment. D. GO term enrichment of RNA present in RHA-RIP following YK-4-279 treatment. E. GO enrichment analysis of RNA were no longer RIP by either protein after YK-4-279 treatment.




Supplementary Figure 8: YK-4-279 does not affect the RNA binding affinity of RHA or EWS-FLI1. A. RHA-RNA binding assay was carried out with the varying concentration of RHA in the presence of 30 µM YK-4-279. RNA-protein complexes were resolved in 6% native PAGE. The affinites were calculated by using GraphPad.

B. EWS-FLI1 and RNA binding assay was carried out with the varying concentration of EWS-FLI1 in the presence of 30 µM YK-4-279. RNA-protein complexes were resolved in 6% native PAGE. The affinites were calculated by using GraphPad.



Supplementary Figure S9. Alignment of RHA and S. cerevisiae Prp43p sequences. The alignment generated by PHYRE indicates that the use of S. cerevisiae Prp43p as a template sequence allows not only for the reliable modeling of RHA's overall fold, but also for the modeling of conserved helicase motifs as described by Fairman-Williams et al. (2010). The query sequence belongs to RHA, the template sequence is Prp43p in the alignment.



Supplementary figure S10: A. Crystal structure of Prp43p (PDB code: 3KX2) shown in cartoon representation with marked helicase motifs as described by Fairman-Williams et al. (2010). The helicase motifs are those determined for RHA by Fairman-Williams and colleagues. B. Superposition of the Prp43p crystal structure (green) and modeled core fragment of RHA (blue). C. The model of RHA with marked helicase motifs.